Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Shanghai Henlius Biotech
National Cancer Institute (NCI)
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Exelixis
Neonc Technologies, Inc.
Emory University
Myeloid Therapeutics
Genentech, Inc.
ImmunityBio, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Incyte Corporation
Bristol-Myers Squibb
University of California, Irvine
The Netherlands Cancer Institute
The Netherlands Cancer Institute
Case Comprehensive Cancer Center
Sarcoma Oncology Research Center, LLC
Daiichi Sankyo
Molecular Templates, Inc.
Taris Biomedical LLC
Sumitomo Pharma America, Inc.
The Netherlands Cancer Institute
Ikena Oncology
University Hospital, Ghent
Gritstone bio, Inc.
Mirati Therapeutics Inc.
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Nektar Therapeutics
Nektar Therapeutics
Infinity Pharmaceuticals, Inc.
Incyte Corporation
PACT Pharma, Inc.
Duke University
Genocea Biosciences, Inc.
AIO-Studien-gGmbH
Weill Medical College of Cornell University
MultiVir, Inc.
M.D. Anderson Cancer Center